Products in transplantation medicine
The cytomegalovirus (CMV) and the Epstein-Barr virus (EBV) are of great importance in transplantation medicine:
Both pathogens are herpes viruses and are present in the world population with an endemic infection rate of 50-60% and 95% respectively. In a healthy immunocompetent person a primary infection usually produces no symptoms, afterwards both viruses persist for a lifetime in their body. A functional, cell-mediated, immune response curbs the spread of the viruses in the body and prevents reactivations and acute illnesses.
Transplant recipients, however, are treated with immunosuppressive drugs to prevent rejection and graft-versus-host reactions, but these severely limit the functioning of the cell-mediated immunity. This can cause reactivations of these viruses, which can result in serious clinical and life-threatening complications in transplant recipients.
CMV is therefore the most important infectious trigger of comorbidities and mortality after transplantation of solid organs and also after allogeneic stem cell transplantation. Reactivations of EBV in transplant recipients can cause severe lymphoproliferative and malign disorders (PTLDs; Post-Transplant Lymphoproliferative Disorders) which often lead to the death of the patient. The antiviral therapy required is sometimes associated with severe side effects, considerable costs and the development of resistant viruses.
The danger of virally caused complications after transplantation is reduced if the virus load is accompanied by a sufficiently large amount of virus-reactive effector cells.
It is therefore desirable to have a reliable assessment and to determine the functionality of the cell-mediated immunity over time to be able to predict virus reactivations and associated complications after transplantation in the future. One of the biggest challenges in the field of transplantation medicine is to establish a personalized immunosuppressive and antiviral therapy for transplant recipients.
Lophius Biosciences is taking up this challenge!
Lophius Biosciences has developed the following products for use with immunocompromised patients:
The T-Track® CMV (or EBV) assay is a diagnostic test for the determination of the functionality of cell mediated immunity (CMI) of CMV (or EBV) seropositive patients. The test enables a semiquantitative evaluation of the CMV- (or EBV-) specific immunocompetence of these patients. The test is not suitable to detect a CMV (or EBV) infection.
The T-Track® CMV (or EBV) assay is a diagnostic test for the determination of the functionality of cell mediated immunity (CMI) of CMV (or EBV) seropositive patients. The test enables a semiquantitative evaluation of the CMV- (or EBV-) specific immunocompetence of these patients.
The test is not suitable to detect a CMV (or EBV) infection.